Connor, Clark & Lunn Investment Management (CC&L)
VBIV

Connor, Clark & Lunn Investment Management (CC&L)’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,163
Closed -$13.6K – 1495
2022
Q4 		$13.6K Sell
1,163
-130
-10% -$2.29K ﹤0.01% 1170
2022
Q3 		$27K Buy
+1,293
New +$34.9K ﹤0.01% 1076
2021
Q3 		– Sell
-1,042
Closed -$105K – 1251
2021
Q2 		$105K Buy
+1,042
New +$102K ﹤0.01% 943

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VBIV Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 1,163 shares — an estimated $13.6K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VBIV in Q2 2021 and held it in 3 quarters. The position peaked at $105K in Q2 2021. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,163 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $13.6K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2021 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $105K in Q2 2021.
  • 95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.